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Editorial on the Research Topic
Approaches to Advance Cancer Vaccines to Clinical Utility
Although cancer vaccines have yielded promising results both in vitro and in animal models, their
translation into clinical application has not been very successful so far, even though encouraging
results from small early phase trials are reported. Junco et al. describes the 10-year follow up
of Heberprovac, a GnRH1 peptide vaccine linked to a tetanic toxoid epitope in prostate cancer
patients. Kjeldsen et al. reports on the 6-year follow up of an indoleamine-2,3-dioxygenase (IDO)
peptide vaccine in non-small cell lung cancer. Both vaccines target endogenous proteins, are
tolerated well long-term, and are safe and show durable responses. Delivering durable benefits
is a unique feature of immune therapy, hence the emergence as “Breakthrough of the Year”
2013 (1). Through the success of immune checkpoint inhibitors, the tumor immunotherapy field
revived and led to important new insights. A better understanding of the functional capacity of
different dendritic cell (DC) subsets and the immunogenicity of tumor antigens, more particularly
of neoantigens, have important implications for the improvement of cancer vaccines. These insights
can guide the development of novel strategies, to enhance the clinical utility of cancer vaccines. The
aim of this Research Topic was therefore to provide a comprehensive overview of current issues
regarding cancer vaccine development with an emphasis on novel approaches toward enhancing
their efficacy.
Current cancer treatments are becoming more and more personalized based on the patient’s
specific tumor characteristics instead of a one-size-fits-all approach (2). This concept is also true for
cancer immunotherapies. Mastelic-Gavillet et al. describes personalized dendritic cell (DC)-based
vaccination andmentions the importance of targeting private tumor antigens, such as neoantigens.
Related to this, Klausen et al. discuss the use of alternative neoantigens resulting from JAK2 and
CALR mutations in hematological malignancies. They also depict the use of regulatory proteins,
PD-L1 and PD-L2, as target antigens. This latter is conceptually similar to the IDO vaccine trial
described by Kjeldsen et al. as the immune target does not need to identify the tumor, but focuses
on the suppressive environment. In the trial of Junco et al., the chosen target is a driver of tumor
growth. Vermaelen discusses the recent efforts taken to improve the selection of tumor antigens to
use as targets in cancer vaccines and their visibility. Xiang et al. identifies the most optimal peptide
for vaccination from three antigens expressed by gynecological tumors.
An important issue to consider when aiming to increase the efficacy of cancer vaccines
is the use of the right adjuvant (3). Besides using DC’s as nature’s adjuvant, several other
approaches are available. In their paper, Xiang et al. describe that polystyrene nanoparticles
can induce T cell responses to tumor antigen peptides although not through conventional
inflammation. Vermaelen gives an overview of the adjuvant formulations that have been
developed to unlock clinically relevant immune responses against cancer antigens, which
comprise both immune stimulation and suppressing the suppressors. However, a reality
check of the vaccine formulations tested clinically in lung cancer shows that clinical
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successes are limited and that traditional approaches from the
infectious diseases’ vaccine field cannot be translated to cancer
treatment as such. Ho et al. also report recent insights in clinically
relevant vaccine adjuvants that impact DC cross-presentation
efficiency. Furthermore, they emphasize that the mode of action
of adjuvants in general, and on antigen cross-presentation in DCs
in particular, is important for the design of novel adjuvants as part
of vaccines able to induce strong cellular immunity. Kartikasari et
al. describe the epigenetic effects of vaccine adjuvants on immune
cells and cancer cells and propose epigenetic interventions that
could improve cancer vaccines.
Another crucial component for the induction of a successful
anti-tumor response is the use or targeting of the right
antigen-presenting cell. DCs are the most professional antigen-
presenting cells but, even between the different DC subsets
significant functional differences have been reported (4). The
review by Clappaert et al. provides a nice overview of the
different myeloid cell types that are present in tumors, including
DCs, and how they can be harnessed for cancer therapy. Since
efficient cross-presentation of tumor antigens is warranted, the
current evidence points toward the cross-presenting DC subset
(CD141+ DC in humans, CD8α+/CD103+ DC in mice) as the
most promising target, which is discussed by Mastelic-Gavillet
et al. and Ho et al. In this respect, Botelho et al. show specific
binding and uptake of a fusion protein of Xcl1 andOVA synthetic
long peptide (SLP) by Xcr1+ DCs. The potent adjuvant effect
on the induced T cell response was associated with sustained
tumor control. Thus, developing Xcl1-SLP-Fc fusion proteins as
an off-the-shelf vaccine targeting cross-presenting DCs might be
an economical and easier alternative to ex vivoDC vaccines. Viral
vectors constitute another approach to modify DCs in situ, as
discussed by Goyvaerts and Breckpot. Their attractiveness lies
in the fact that they can be targeted and then simultaneously
deliver the encoded tumor antigen to antigen-presenting cells as
well as behaving as Th1-polarizing adjuvant via the viral vector
backbone. However, the antiviral immunogenicity also carries
their weakness for which solutions are discussed.
DC targeting can also be achieved via so-called in situ
vaccination approaches, to induce local release of tumor antigens
from the tumor itself (5). Yasmin-Karim et al. report that
stereotactic body radiation therapy (SBRT) synergizes with
intratumoral injection of agonistic anti-CD40, resulting in
regression of non-treated contralateral tumors and formation of
long-term immunologic memory in a pancreatic mouse model.
Locy et al. discuss how oncolytic viruses, radiotherapy, physical
therapies, growth factors, and cytokines can stimulate anti-tumor
immune responses through the induction of immunogenic cell
death, the attraction of different immune cell populations and
by alleviating immune suppression. Next challenges for in situ
vaccination include the accessibility of the tumor and the need to
develop approaches to circumvent local immunosuppression.
FUTURE PERSPECTIVES
Although it has come a long way, there is still a lot of room for
cancer vaccine optimization. First, the best vaccination approach
might differ for “hot tumors (immunogenic)” vs. “cold tumors
(non-immunogenic).” Vermaelen describes the importance to
focus on lymphocyte entrance and the local suppression in the
tumor mediated by receptors/ligands (checkpoints), cells (Treg,
MDSC), and metabolism (IDO, adenosine, lack of arginine, etc).
Strategies to handle tumor associated myeloid cells are more
extensively elaborated by Clappaert et al.
Second, biomarkers can guide physicians in their treatment
decision to obtain a faster selection of the most effective
treatment. Highly reliable molecular and/or cellular biomarkers
for vaccine efficacy are still to be identified. Mastelic-Gavillet
et al. summarizes that in non-small cell lung cancer BDCA1+
DC/BDCA3+ DC ratio in peripheral blood correlated with
survival, as did CD56dim cytotoxic NK cells in glioblastoma.
The expression of chemokine receptor CXCR4 on CD8+ T
cells and CD32 on monocytes correlated with immunological
responders. However, these still require further validation.
Epigenetic mapping could be a promising next type of biomarker,
but is still in its infancy according to Kartikasari et al.
Finally, the indication for which the vaccine developed is
of major importance. Due to the highly immunosuppressive
nature of the tumor microenvironment, it is clear that cancer
vaccination strategies will have to be integrated in combination
therapies to tackle tumor-induced immunosuppression (6).
Current standard of care therapies can have immune modulating
properties or serve as adjuvant. Some are described by
Locy et al., as mentioned above. Klausen et al. mentions
upregulation of cancer testis antigens by hypomethylating agents
given to patients with high-risk myelodysplastic syndrome.
Practically, the influence of different standards of care in
each indication need to be taken into account to foster
clinical implementation, in particular when vaccination would
not be applied as a first line treatment. Equally important,
is looking at the development of new therapies in that
indication that might become the next standard of care
and existing therapies for other indications that can serve
as good adjuvants as mentioned by Ho et al. The review
paper of van Willigen et al. delineates the position of
DC therapy in the current and future cancer treatment
landscape for glioblastoma, melanoma, prostate cancer, and renal
cell carcinoma.
Personalization, as indicated in this Research Topic, either
through the in situ or ex vivo use of the right type of
autologous cell and/or by choosing the best specific target
for each tumor or its microenvironment currently holds
a lot of promise. Optimized clinical trials will now have
to reveal whether this brings cancer vaccine efficacy to
the next level.
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